Literature DB >> 8662104

Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.

G Görres1, A Kaim, A Otte, M Götze, J Müller-Brand.   

Abstract

To determine bone mineral density in patients with differentiated thyroid carcinoma receiving thyroxine replacement therapy in suppressive doses, we studied 65 patients (47 women and 18 men; age 25-83 years, mean+/-SD 52.5+/-15.4 years). Patients were free of thyroid cancer in clinical and laboratory examinations at the time of the study. Bone mineral density of the lumbar spine and both hips was measured by dual-energy X-ray absorptiometry. There was no decrease in bone density in either 32 postmenopausal or 15 premenopausal women compared with an age- and sex-matched control group, nor was any decrease in bone density found in men. Our data suggest that thyroxine treatment in suppressive doses in patients with differentiated thyroid carcinoma is not a risk factor for the development of osteoporosis.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8662104     DOI： 10.1007/bf00834532

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


  9 in total

1.  Long-term thyroxine treatment and bone mineral density.

Authors:  J A Franklyn; J Betteridge; J Daykin; R Holder; G D Oates; J V Parle; J Lilley; D A Heath; M C Sheppard
Journal:  Lancet       Date:  1992-07-04       Impact factor: 79.321

Review 2.  Involutional osteoporosis.

Authors:  B L Riggs; L J Melton
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

3.  Relative contributions of aging and estrogen deficiency to postmenopausal bone loss.

Authors:  L S Richelson; H W Wahner; L J Melton; B L Riggs
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

4.  Reduced bone mineral content in totally thyroidectomized patients: possible effect of calcitonin deficiency.

Authors:  M T McDermott; G S Kidd; P Blue; V Ghaed; F D Hofeldt
Journal:  J Clin Endocrinol Metab       Date:  1983-05       Impact factor: 5.958

5.  Variation between femurs as measured by dual energy X-ray absorptiometry (DEXA).

Authors:  M L Hall; J Heavens; P J Ell
Journal:  Eur J Nucl Med       Date:  1991

6.  A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.

Authors:  T Diamond; L Nery; I Hales
Journal:  J Clin Endocrinol Metab       Date:  1991-06       Impact factor: 5.958

7.  Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.

Authors:  C M Florkowski; B E Brownlie; J R Elliot; E M Ayling; J G Turner
Journal:  N Z Med J       Date:  1993-10-27

8.  Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases.

Authors:  N A Samaan; Y K Maheshwari; S Nader; C S Hill; P N Schultz; T P Haynie; R C Hickey; R L Clark; H Goepfert; M L Ibanez; C E Litton
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

9.  Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine.

Authors:  G M Stall; S Harris; L J Sokoll; B Dawson-Hughes
Journal:  Ann Intern Med       Date:  1990-08-15       Impact factor: 25.391
  9 in total
  9 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 2.  Adverse effects of thyroid hormones.

Authors:  J B Williams
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

3.  Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma.

Authors:  Jordi L Reverter; Eulàlia Colomé; Susana Holgado; Eva Aguilera; Berta Soldevila; Lourdes Mateo; Anna Sanmartí
Journal:  Endocrine       Date:  2010-04-16       Impact factor: 3.633

4.  Bone demineralization in postmenopausal women: role of anamnestic risk factors.

Authors:  Sandro La Vignera; Rosita A Condorelli; Enzo Vicari; Chiara Nicoletti; Aldo E Calogero
Journal:  Int J Endocrinol       Date:  2012-07-26       Impact factor: 3.257

5.  Effects of Levothyroxine and thyroid stimulating hormone on bone loss in patients with primary hypothyroidism.

Authors:  Mansoor Karimifar; Farah Esmaili; Amirhossein Salari; Ali Kachuei; Ziba Faragzadegan; Mozhgan Karimifar
Journal:  J Res Pharm Pract       Date:  2014-07

Review 6.  Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients.

Authors:  Maria Papaleontiou; Sarah T Hawley; Megan R Haymart
Journal:  Oncologist       Date:  2015-12-09

Review 7.  Long-term treatment-related morbidity in differentiated thyroid cancer: a systematic review of the literature.

Authors:  William Ae Parker; Ovie Edafe; Sabapathy P Balasubramanian
Journal:  Pragmat Obs Res       Date:  2017-05-16

8.  Risk of Osteoporosis and Fractures in Patients with Thyroid Cancer: A Case-Control Study in U.S. Veterans.

Authors:  Maria Papaleontiou; Mousumi Banerjee; David Reyes-Gastelum; Sarah T Hawley; Megan R Haymart
Journal:  Oncologist       Date:  2019-06-04

9.  Modeling the effect of levothyroxine therapy on bone mass density in postmenopausal women: a different approach leads to new inference.

Authors:  Babak Mohammadi; Vahid Haghpanah; Seyed Mohammad Tavangar; Bagher Larijani
Journal:  Theor Biol Med Model       Date:  2007-06-09       Impact factor: 2.432
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.